Several hematologic malignancies also express varying levels of CD38 [126–128], such as multiple myeloma (MM), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). This evidence concerns the gene CD38 and Miyoshi myopathy.